This license agreement continues to build on Biosion’s efforts to create and develop meaningful biologics to treat resistant, relapsed and residual disease for patients worldwide.

Newark, DE, USA, Nanjing, China – December 13, 2021.  Biosion, Inc. (“Biosion”), a global, clinical stage biotech company announced today that OBI Pharma Inc. (“OBI Pharma”) and Biosion have signed an exclusive license agreement providing OBI Pharma worldwide rights, excluding China to Biosion’s proprietary anti-Trop2 humanized monoclonal antibody, BSI04702. The license agreement enables OBI Pharma to conduct further preclinical and clinical development, registration, and commercialization of BSI04702 as an Antibody Drug Conjugate and other derivative products. Under the terms of the agreement, OBI Pharma will pay license fees to Biosion, including an upfront payment, future development milestones and net sales royalties.  The specific terms of the agreement were not disclosed.

“The licensing of our anti-TROP-2 mAb to OBI Pharma for global development further exhibits the strength of our Discovery engine and proprietary SynTracerTM HT-endocytosis platform to identify superior mAbs, ideal as ADCs” said Dr. Hugh Davis, Chief Operations Officer of Biosion, Inc. and President of Biosion USA.  “We are looking forward to partnering with OBI Pharma to advance BSI-04702 into the clinic and making a difference for patients worldwide.”

BSI04702 is an anti-TROP2 humanized monoclonal antibody with differentiated properties relative to existing mAbs that bind TROP-2.  It was created through Biosion’s proprietary Discovery engine and SynTracerTM HT-endocytosis Platform.

About Biosion, Inc.

For more information and full pipeline details, please visit www.biosion.com.

About OBI Pharma , Inc.

For more information and full pipeline details, please visit www.obipharma.com.

Media and Investor Contact:

Frank Liu, Ph.D.

Senior Director, Business Development

Biosion USA, Inc.

Phone: +1-302-998-5126

E-mail: Frank.Liu@Biosion.com